Literature DB >> 18956252

Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.

F K Trefz1, D Scheible, H Götz, G Frauendienst-Egger.   

Abstract

BACKGROUND: The value of genotyping to identify tetrahydrobiopterin-responsive (BH(4)-responsive) patients with phenylalanine hydroxylase (PAH) deficiency is a matter of debate.
METHODS: We reviewed 250 cases of patients with PAH deficiency, using published data from 198 cases and unpublished data from 52 cases of patients attending our own clinic. Patients underwent analyses for BH(4) load and genetic mutations. Partial and full BH(4) responses were defined as a 10-29% decrease and a >or=30% decrease from baseline in blood phenylalanine levels, respectively. BH(4)-responsive alleles were identified from BH(4)-responsive patients as either homozygous for a specific allele or compound heterozygous for that allele with a null mutation.
RESULTS: Most inconsistencies between observed genotype and BH(4) response were associated with mutations in the regulatory domain of PAH (p.R68S, p.I65T, p.L48S and p.F39C), where 20/62 alleles (32.2%) were non-responsive. In the catalytic domain (mutations p.Y414C, p.R261Q, p.E390G, p.A300S, p.R241C, p.A403V and p.V388M), only 8/125 alleles (6.4%) were non-responsive. Seven patients had a genotype with two BH(4)-responsive alleles resulting in no response or only a partial response to BH(4). Ten patients had identical genotypes but inconsistent responses in BH(4) load.
CONCLUSIONS: These results show that BH(4) non-responsiveness is associated with genotype. However, patients with mutations in the regulatory domain show inconsistent results. In patients with two responsive alleles, non-responsiveness may be related to negative inter-allelic complementation. In patients with the same genotype and inconsistent results for BH(4) load, external factors such as intestinal absorption of BH(4), catabolic conditions or other genetic factors may be responsible. Further in vitro studies are necessary to clarify the genotype-phenotype correlation in patients with BH(4)-responsive PKU.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956252     DOI: 10.1007/s10545-008-0940-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  Tetrahydrobiopterin-responsive hyperphenylalaninaemia due to homozygous mutations in the phenylalanine hydroxylase gene.

Authors:  Nenad Blau; Caroline Bernegger; Fritz K Trefz
Journal:  Eur J Pediatr       Date:  2003-03       Impact factor: 3.183

2.  Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin.

Authors:  Friedrich K Trefz; Dagmar Scheible; Georg Frauendienst-Egger; Herbert Korall; Nenad Blau
Journal:  Mol Genet Metab       Date:  2005-10-20       Impact factor: 4.797

3.  Tetrahydrobiopterin responsiveness in patients with phenylketonuria.

Authors:  Belén Pérez-Dueñas; Maria Antonia Vilaseca; Anna Mas; Nilo Lambruschini; Rafael Artuch; Lilian Gómez; Julia Pineda; Alejandra Gutiérrez; Montse Mila; Jaume Campistol
Journal:  Clin Biochem       Date:  2004-12       Impact factor: 3.281

4.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  S Kure; D C Hou; T Ohura; H Iwamoto; S Suzuki; N Sugiyama; O Sakamoto; K Fujii; Y Matsubara; K Narisawa
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

5.  Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene.

Authors:  Haruo Shintaku; Shigeo Kure; Toshihiro Ohura; Yoshiyuki Okano; Misao Ohwada; Naruji Sugiyama; Nobuo Sakura; Ichiro Yoshida; Makoto Yoshino; Yoichi Matsubara; Ken Suzuki; Kikumaro Aoki; Teruo Kitagawa
Journal:  Pediatr Res       Date:  2003-12-17       Impact factor: 3.756

6.  Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations.

Authors:  Angel L Pey; Belén Pérez; Lourdes R Desviat; Maria Angeles Martínez; Cristina Aguado; Heidi Erlandsen; Alejandra Gámez; Raymond C Stevens; Matthías Thórólfsson; Magdalena Ugarte; Aurora Martínez
Journal:  Hum Mutat       Date:  2004-11       Impact factor: 4.878

7.  Co-expression of different subunits of human phenylalanine hydroxylase: evidence of negative interallelic complementation.

Authors:  João Leandro; Cátia Nascimento; Isabel Tavares de Almeida; Paula Leandro
Journal:  Biochim Biophys Acta       Date:  2006-02-28

8.  Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.

Authors:  Harvey Levy; Barbara Burton; Stephen Cederbaum; Charles Scriver
Journal:  Mol Genet Metab       Date:  2007-12       Impact factor: 4.797

9.  Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH.

Authors:  Angel L Pey; Lourdes R Desviat; Alejandra Gámez; Magdalena Ugarte; Belén Pérez
Journal:  Hum Mutat       Date:  2003-04       Impact factor: 4.878

10.  Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  Marcel R Zurflüh; Johannes Zschocke; Martin Lindner; François Feillet; Céline Chery; Alberto Burlina; Raymond C Stevens; Beat Thöny; Nenad Blau
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

View more
  20 in total

1.  Clinical utility gene card for: Phenylketonuria.

Authors:  Johannes Zschocke; Thomas Haverkamp; Lisbeth Birk Møller
Journal:  Eur J Hum Genet       Date:  2011-09-14       Impact factor: 4.246

2.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

3.  Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S.

Authors:  Maja Djordjevic; Kristel Klaassen; Adrijan Sarajlija; Natasa Tosic; Branka Zukic; Bozica Kecman; Milena Ugrin; Vesna Spasovski; Sonja Pavlovic; Maja Stojiljkovic
Journal:  JIMD Rep       Date:  2012-10-13

4.  Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Authors:  M L Couce; M D Bóveda; E Valerio; A Pérez-Muñuzuri; J M Fraga
Journal:  JIMD Rep       Date:  2011-09-06

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

6.  Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Authors:  Rani H Singh; Meghan E Quirk
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

Review 7.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

8.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria.

Authors:  Meghan E Quirk; Steven F Dobrowolski; Benjamin E Nelson; Bradford Coffee; Rani H Singh
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

9.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09

10.  Influence of PAH Genotype on Sapropterin Response in PKU: Results of a Single-Center Cohort Study.

Authors:  Sarah Leuders; Eva Wolfgart; Torsten Ott; Marcel du Moulin; Agnes van Teeffelen-Heithoff; Lydia Vogelpohl; Ulrike Och; Thorsten Marquardt; Josef Weglage; Reinhold Feldmann; Frank Rutsch
Journal:  JIMD Rep       Date:  2013-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.